Business
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 TrialLow dose (Z)-endoxifen was well tolerated and demonstrated promising rapid activity in reducing 3-wk Ki-67 and F
By: manilatimes
- Nov 01 2024
- 0
- 0 Views
Share this page
Guest Posts by Easy Branches-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer&url=https://easybranches.com/feed/ph/business/10604283&media=https://easybranches.com/feed/uploads/2024/11/2e0ee7fb024262c2296476c076a54d4e.jpg){kind=link}
